UroGen Pharma Announces Commencement of Public Offering of Prefunded Common Shares and Warrants

06/17/2024 – 4:46 p.m.

PRINCETON, NJ, June 17, 2024 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to the development and commercialization of innovative solutions to treat urothelial and specialty cancers, today announced that it has launched a public subscription offering, subject to market and other conditions, issue and sell its common shares and pre-funded warrants. In connection with the proposed offering, UroGen also plans to grant the underwriters a 30-day option to purchase up to an additional amount 15% of the total number of shares of common stock (including the underlying pre-funded warrants) offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. All shares of common stock and pre-funded warrants to be sold in the proposed offering will be offered by UroGen.

TD Cowen and Guggenheim Securities are acting as joint book-running managers for the proposed offering. Oppenheimer & Co. is acting as lead manager for the proposed offering. Ladenburg Thalmann is acting as co-manager of the proposed offering.

The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, filed with the Securities and Exchange Commission (the “SEC”) and declared effective on November 29, 2022. preliminary prospectus supplement and The accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement (when available) and the accompanying prospectus may be obtained by contacting TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495 -9846 or by email to TD. [email protected]; or Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, telephone: (212) 518-5548, e-mail: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be illegal before registration. or qualification under the securities laws of any such state or other jurisdiction.

About UroGen Pharma Ltd.

UroGen is a biotechnology company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® Reverse Thermal Hydrogel, a proprietary hydrogel-based sustained release platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to allow longer exposure of urinary tract tissues to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and the investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle-invasive bladder cancer are designed for the removal of tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey, and operates in Israel.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding, among other things, UroGen’s expectations regarding achievement and timing of the proposed offer; UroGen’s expectations regarding granting the underwriters a 30-day option to purchase additional shares; the potential of RTGel^® improve the therapeutic profiles of existing drugs; and the potential of UroGen’s sustained-release technology to make local delivery more effective compared to other treatment options. The words “expects”, “potential”, “proposed”, “may”, “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words . Actual results or events could differ materially from the plans, intentions and expectations disclosed in such forward-looking statements as a result of various important factors, including risks relating to the inability of UroGen, or the inability of the underwriters, to satisfy the closing conditions of the proposed offer; uncertainties associated with UroGen’s ongoing and planned clinical trials; UroGen RTGel^® the technology may not work as expected; UroGen may not successfully develop or receive regulatory approval of any other products incorporating RTGel^® technology; the impacts of general macroeconomic and geopolitical conditions, high inflation and uncertainty in credit and financial markets on UroGen’s business, clinical trials and financial condition; and other risks and uncertainties described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 13, 2024, and in other documents filed by UroGen with the SEC from time to time. The events and circumstances discussed in these forward-looking statements may not occur, and UroGen’s actual results may differ materially and adversely from those anticipated or implied. Any forward-looking statements contained in this press release speak only as of the date hereof, and UroGen expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise .

INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
[email protected]
609-460-3588 ext. 3588 1093

MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
[email protected]
609-460-3583 ext. 3583 1083

FAQs

What is the purpose of the UroGen Pharma IPO announced on June 17, 2024?

The public offering aims to issue and sell common shares and pre-funded warrants, potentially increasing the capital of UroGen Pharma.

Will UroGen Pharma’s public offering include an option for subscribers?

Yes, UroGen Pharma plans to grant underwriters a 30-day option to purchase an additional 15% of the total shares offered.

Which financial institutions manage the public offering of UroGen Pharma?

TD Cowen and Guggenheim Securities act as joint lead managers, with Oppenheimer & Co. as lead manager and Ladenburg Thalmann as co-manager.

What are the potential risks associated with the public offering of UroGen Pharma?

Risks include uncertainty regarding the consummation, size and terms of the offering, as well as potential dilution of current shareholder value.

Where can I find the UroGen Pharma public offering prospectus?

The prospectus can be viewed on the SEC’s website or obtained from TD Securities or Guggenheim Securities.